Skip to main content

Table 1 Demographics of GC patients treated with S-1 adjuvant chemotherapy

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factors N = 100
Sex (M/F) 73 / 27
Age (< 65/≥65 years) 41 / 59
Tumor size (< 60/≥60 mm) 48 / 52
Histologic type (Diff/Undiff) 35 / 65
pT (1/2/3/4) 5 / 12 / 41 / 42
pN (0/1/2/3) 14 / 25 / 31 / 30
pStage (II/III) 39 / 61
Lymphatic invasion (+/−) 80 / 20
Venous invasion (+/−) 78 / 22
pNLR (+/−) 50 / 50
iNLR (+/−) 26 / 74
fNLR (+/−) 38 / 62
pPLR (+/−) 50 / 50
iPLR (+/−) 50 / 50
fPLR (+/−) 35 / 65
Recurrence (+/−) 35 / 65
Site of relapse (H/P/LYM/Lo) 6 / 12 / 17 / 2
Outcome (D/A) 24 / 76
  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR or pPLR, preoperative neutrophil or platelet-to-lymphocyte ratio; iNLR and iPLR, the ratio of the NLR or PLR on the initial day of adjuvant chemotherapy to the pNLR or pPLR; fNLR and fPLR, the ratio of the NLR or PLR on the final day of adjuvant chemotherapy to the iNLR or iPLR; H, hematogenous metastasis; P, peritoneal metastasis; LYM, lymph node metastasis; Lo, local recurrence; D/A, dead or alive
\